Targeted kinase inhibitors in lung cancer: From EGFR to patients

Giovanni Apolone; Carlo La Vecchia; Silvio Garattini

doi:10.1016/j.ejca.2005.10.013

Related publications

Article2023

Receptor tyrosine kinase inhibitors in cancer

Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, Sahar Palizdar, Roya Khorram, Reza Vafadar, Masoud Ghanaatian, Fatemeh Rezaei‐Tazangi, Payam Baziyar, Amirhossein Ahmadi, Michael R Hamblin, Amir Reza Aref

Article2025

C3d-targeted complement inhibitors to correct complement dysregulation in aHUS patients

Valeria Guaschino, Donata Santarsiero, Sara Gastoldi, Joshua M. Thurman, V. Michael Holers, Shelia M. Violette, Fei Liu, Kelly Fahnoe, Chiara Guarinoni, Ariela Benigni, Giuseppe Remuzzi, Marina Noris, Sistiana Aiello

Preprint2022

Receptor Tyrosine Kinase Inhibitors in Cancer Immunotherapy

Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, Sahar Palizdar, Roya Khorram, Reza Vafadar, Halimeh Mobarak, Amirhossein Ahmadi, Michael R Hamblin, Amir Reza Aref

Article2019

Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy

Else Driehuis, Sacha Spelier, Irati Beltran Hernandez, Remco de Bree, Stefan M. Willems, Hans Clevers, Sabrina Oliveira

Article2021

Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis.

Hongjoo J. Lee, Gwang Hun Jeong, H. Li, M S Kim, J S Kim, S J Park, Yi Han, Keum Hwa Lee, Andreas Kronbichler, Seok-Il Hong, Ramy Abou Ghayda, Claudio Luchini, Alessia Nottegar, A Koyanagi, Lee Smith, Linu Abraham Jacob, Elena Dragioti, Joaquim Raduà, Sarah Cargnin, Salvatore Terrazzino, Terry Thompson, Dong Keon Yon,